Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Core IM | Internal Medicine Podcast

#192 Debate on First-Line Medications for Diabetes

05 Nov 2025

Description

SGLT-2i vs. GLP-1? vs Metformin? How do you balance the cost and coverage of first-line options like metformin, SGLT-2, and GLP-1s? How do you choose between SGLT-2 and GLP-1s for comorbidities like CAD or CKD? And how do you weigh their side effects and practical use?🔹 Sponsor:Use the code "CORE30" for 30% off: https://www.coreimpodcast.com/MKSAP🔹 Transcript and Show NotesTimestamps:(01:43) | Case 1: Managing Uncontrolled Diabetes in a 47-Year-Old Male(07:15) | Understanding Cost and Insurance Barriers in Diabetes Care(09:26) | Case 2: Addressing Weight Gain and Financial Stress in a 52-Year-Old Male(14:16) | Case 3: Managing Coronary Artery Disease and CKD in a 66-Year-Old Male(19:41) | Case 4: Severe Obesity and Pain Management in a 59-Year-Old Female(24:19) | Case 5: High A1C and Vascular Comorbidities in a 67-Year-Old Female (35:34) | Weighing Side Effects and Practical Use of GLP-1 and SGLT2 InhibitorsTags: CoreIM, Primary Care, Endocrinology, Diabetes Mellitus, Type 2 Diabetes, Type 1 Diabetes, Metformin, GLP-1, SGLT2, Insulin, CGM, A1C, DKA, Medical Education, Clinical Reasoning, Hospital MedicineFind the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840Our Sponsors:* Check out Branch Basics: https://branchbasics.com/COREIM and use the code CoreIM for 15% * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com* Check out Washington Red Raspberries: https://redrazz.orgAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.